. Author manuscript; available in PMC: 2014 Jan 1.

Published in final edited form as: Neuroepidemiology. 2012 Oct 24;40(2):73–84. doi: 10.1159/000342761

Table 2.

Summary of large prospective cohort studies of aPL and thrombo-occlusive events

Study	Authors	Year	aPL assay	Outcome	Risk	95% CI	Follow-up
PHS	Ginsburg et al.	1992	aCL	Stroke	ns	-	5 years ♂
				DVT or PE	RR 5.3	1.6, 18.3	5 years ♂
HHS	Brey et al.	2001	anti-β₂GPI	Stroke	OR 2.2	1.5, 3.4	15 years ♂
					OR 1.5	1.0, 2.3	20 years ♂
				MI	OR 1.8	1.2, 2.6	15 years ♂
					OR 1.5	1.1, 2.1	20 years ♂
FCOS	Janardhan et al.	2004	aCL	Stroke or TIA	HR 2.6	1.3, 5.4	11 years ♀
					HR 1.3	0.7, 2.4	11 years ♂

PHS: Physicians Health Study; HHS: Honolulu Heart Study; FCOS: Framingham Cohort and Offspring Study; aCL: anticardiolipin antibodies; anti-β₂GPI: antibodies to β₂-glycoprotein I; DVT: deep vein thrombosis; PE: pulmonary embolism; MI: myocardial infarction; TIA: transient ischemic attack; ns: not significant; RR: relative risk; OR: odds ratio; HR: hazard ratio; CI: confidence interval